Brother Pharmaceutical
Brother Pharmaceutical Co., Ltd., commonly referred to as Brother Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in the early 2000s, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on generic medications and active pharmaceutical ingredients (APIs). With a strong operational presence across Asia and expanding into international markets, Brother Pharmaceutical is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic solutions that cater to various medical needs, setting them apart through rigorous quality control and adherence to international standards. Notable achievements include certifications from global regulatory bodies, positioning Brother Pharmaceutical as a trusted name in the industry. Their dedication to research and development continues to drive their market presence, ensuring they remain at the forefront of pharmaceutical advancements.
DitchCarbon Score
How does Brother Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Metal Fabrication industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Brother Pharmaceutical's score of 10 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Brother Pharmaceutical's reported carbon emissions
Brother Pharmaceutical, headquartered in CN, currently does not have publicly available data on its carbon emissions or specific climate commitments. Without emissions data, it is challenging to assess their performance in terms of Scope 1, 2, or 3 emissions. Additionally, there are no documented reduction targets or initiatives outlined by the company, which limits the ability to evaluate their climate strategy or commitments to sustainability. As the pharmaceutical industry increasingly focuses on reducing carbon footprints, it is essential for companies like Brother Pharmaceutical to establish clear targets and transparent reporting to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Brother Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
